Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 10.55 M

Oncopeptides AB (publ) Net Cash Used Provided By Financing Activities is USD 10.55 M for the year ending December 31, 2023, a -71.85% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Oncopeptides AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 37.47 M, a -67.08% change year over year.
Oncopeptides AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 113.85 M, a -29.02% change year over year.
Oncopeptides AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 160.40 M, a 21.94% change year over year.
Oncopeptides AB (publ) Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 131.54 M, a 283.50% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years